SeaStar Medical will present at a virtual conference on its therapies for critically ill patients on February 5, 2026.
Quiver AI Summary
SeaStar Medical Holding Corporation, a healthcare company focused on improving treatments for critically ill patients experiencing organ failure, announced that CEO Eric Schlorff will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on February 5, 2026. Interested participants can register to view the live presentation and a replay will be available on the company's website after February 9. SeaStar's first commercial product, the QUELIMMUNE (SCD-PED) therapy, received FDA approval in 2024 for treating life-threatening acute kidney injury in critically ill pediatric patients. The Selective Cytopheretic Device (SCD) technology has also received Breakthrough Device Designation for six indications. Currently, the company is running a pivotal trial for SCD therapy in adult patients with acute kidney injury requiring continuous renal replacement therapy. For more details, visit their website or contact investor relations.
Potential Positives
- Eric Schlorff, CEO of SeaStar Medical, is presenting at a reputable investment conference, indicating strong interest in the company's developments and enhancing visibility among potential investors.
- The QUELIMMUNE (SCD-PED) therapy being the only FDA-approved product for life-threatening acute kidney injury in critically ill pediatric patients underscores the company's leadership in addressing significant unmet medical needs.
- SeaStar Medical's Selective Cytopheretic Device (SCD) therapy receiving Breakthrough Device Designation for multiple therapeutic indications suggests accelerated regulatory pathways, which could lead to faster market access and improved financial returns.
- The ongoing NEUTRALIZE-AKI pivotal trial highlights the company's commitment to developing treatments for adult patients with acute kidney injury, addressing a critical healthcare gap and potentially expanding its market reach.
Potential Negatives
- The announcement lacks detailed financial information or projections that could provide insight into the company's growth or profitability, leaving investors without critical context for the investment opportunity.
- There is no mention of existing competition or market challenges that SeaStar Medical may face, which could give an incomplete picture of the company's market positioning and potential risks.
- The press release does not address any regulatory challenges or hurdles beyond the FDA approval, which may raise concerns about future product development and market viability.
FAQ
What is SeaStar Medical's focus and mission?
SeaStar Medical focuses on transforming treatments for critically ill patients facing organ failure and potential loss of life.
When will Eric Schlorff present at the Noble Capital Markets conference?
Eric Schlorff will present on Thursday, February 5th at 11:30 am Eastern Time.
How can investors view the SeaStar Medical presentation?
Investors can register and view the presentation through the Virtual Equity Conference Registration link.
What is the QUELIMMUNE (SCD-PED) therapy?
QUELIMMUNE (SCD-PED) therapy is SeaStar Medical’s FDA-approved treatment for life-threatening acute kidney injury in critically ill pediatric patients.
What clinical trial is SeaStar Medical currently conducting?
SeaStar Medical is conducting the NEUTRALIZE-AKI pivotal trial for its SCD therapy in adult patients with acute kidney injury.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ICU Insider Trading Activity
$ICU insiders have traded $ICU stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ICU stock by insiders over the last 6 months:
- HEEL KENNETH VAN has made 2 purchases buying 35,000 shares for an estimated $30,812 and 0 sales.
- KEVIN CHUNG (Chief Medical Officer) purchased 10,000 shares for an estimated $8,000
- MICHAEL MESSINGER (Chief Financial Officer) purchased 14,500 shares for an estimated $5,098
- JENNIFER A BAIRD purchased 4,200 shares for an estimated $987
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ICU Hedge Fund Activity
We have seen 10 institutional investors add shares of $ICU stock to their portfolio, and 15 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC added 319,879 shares (+556.3%) to their portfolio in Q3 2025, for an estimated $182,331
- GEODE CAPITAL MANAGEMENT, LLC added 190,094 shares (+276.2%) to their portfolio in Q3 2025, for an estimated $108,353
- MILLENNIUM MANAGEMENT LLC added 179,673 shares (+inf%) to their portfolio in Q3 2025, for an estimated $102,413
- UBS GROUP AG removed 81,100 shares (-88.6%) from their portfolio in Q3 2025, for an estimated $46,226
- TRINITY FINANCIAL ADVISORS LLC removed 42,500 shares (-85.0%) from their portfolio in Q4 2025, for an estimated $10,200
- VIRTU FINANCIAL LLC removed 37,832 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $21,564
- DYNAMIC ADVISOR SOLUTIONS LLC removed 26,350 shares (-90.0%) from their portfolio in Q4 2025, for an estimated $6,324
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
DENVER, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Thursday, February 5th at 11:30 am Eastern Time.
Interested investors and guests of SeaStar Medical can register and view the live investor presentations here: Virtual Equity Conference Registration .
A replay of the SeaStar Medical presentation will be available on Monday, February 9 th after 11:30 am Eastern Time on the Company's website and can be accessed here . The replay will be available for up to 30 days following its posting.
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The QUELIMMUNE (SCD-PED) therapy is SeaStar Medical’s first commercial product based on its patented Selective Cytopheretic Device (SCD) technology. The QUELIMMUNE (SCD-PED) therapy was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting the NEUTRALIZE-AKI pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT), a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X .
Contact:
SeaStar Investor Relations:
[email protected]
